PH12013501924A1 - Anticoagulant antidotes - Google Patents
Anticoagulant antidotesInfo
- Publication number
- PH12013501924A1 PH12013501924A1 PH1/2013/501924A PH12013501924A PH12013501924A1 PH 12013501924 A1 PH12013501924 A1 PH 12013501924A1 PH 12013501924 A PH12013501924 A PH 12013501924A PH 12013501924 A1 PH12013501924 A1 PH 12013501924A1
- Authority
- PH
- Philippines
- Prior art keywords
- antidotes
- anticoagulant
- anticoagulant antidotes
- anticoagulants
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161469207P | 2011-03-30 | 2011-03-30 | |
| PCT/EP2012/055397 WO2012130834A1 (en) | 2011-03-30 | 2012-03-27 | Anticoagulant antidotes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12013501924A1 true PH12013501924A1 (en) | 2017-10-25 |
Family
ID=45876804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2013/501924A PH12013501924A1 (en) | 2011-03-30 | 2012-03-27 | Anticoagulant antidotes |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8821871B2 (https=) |
| EP (1) | EP2691156A1 (https=) |
| JP (1) | JP2014515740A (https=) |
| KR (1) | KR20140009437A (https=) |
| CN (1) | CN103476459A (https=) |
| AP (1) | AP2013007046A0 (https=) |
| AR (1) | AR085758A1 (https=) |
| BR (1) | BR112013025031A2 (https=) |
| CA (1) | CA2827787A1 (https=) |
| CL (1) | CL2013002551A1 (https=) |
| CO (1) | CO6771448A2 (https=) |
| EA (1) | EA201301090A1 (https=) |
| EC (1) | ECSP13012997A (https=) |
| IL (1) | IL227653A0 (https=) |
| MA (1) | MA34978B1 (https=) |
| MX (1) | MX2013011092A (https=) |
| PE (1) | PE20140964A1 (https=) |
| PH (1) | PH12013501924A1 (https=) |
| SG (1) | SG193552A1 (https=) |
| TN (1) | TN2013000388A1 (https=) |
| TW (1) | TW201302796A (https=) |
| UY (1) | UY33994A (https=) |
| WO (1) | WO2012130834A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| DK2785700T3 (en) | 2011-11-29 | 2016-06-13 | Perosphere Inc | Agent for preventing the action of anti-coagulants. |
| SG11201509982UA (https=) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
| KR102322425B1 (ko) * | 2013-07-30 | 2021-11-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체 |
| KR101523503B1 (ko) * | 2013-09-17 | 2015-05-29 | 강원대학교산학협력단 | 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물 |
| WO2015059159A1 (en) | 2013-10-25 | 2015-04-30 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
| EP2980218A1 (en) * | 2014-07-30 | 2016-02-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors |
| US20210228742A1 (en) * | 2018-04-27 | 2021-07-29 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | In vivo gene therapy using intraosseous delivery of a lentiviralgene construct |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| HU215180B (hu) | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| AT404357B (de) | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
| DE19605126A1 (de) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
| US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF |
| US6440417B1 (en) | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2002241922B2 (en) | 2001-01-17 | 2007-10-25 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| CA2505316C (en) | 2002-11-08 | 2014-08-05 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
| KR102069498B1 (ko) | 2007-09-28 | 2020-01-23 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법 |
| JP2013502449A (ja) * | 2009-08-24 | 2013-01-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ダビガトランエテキシレート過剰投与による活性炭の緊急処置 |
| AR079944A1 (es) * | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
-
2012
- 2012-03-27 SG SG2013070719A patent/SG193552A1/en unknown
- 2012-03-27 MA MA36273A patent/MA34978B1/fr unknown
- 2012-03-27 EP EP12710300.0A patent/EP2691156A1/en not_active Withdrawn
- 2012-03-27 KR KR1020137025877A patent/KR20140009437A/ko not_active Withdrawn
- 2012-03-27 PH PH1/2013/501924A patent/PH12013501924A1/en unknown
- 2012-03-27 EA EA201301090A patent/EA201301090A1/ru unknown
- 2012-03-27 PE PE2013002078A patent/PE20140964A1/es not_active Application Discontinuation
- 2012-03-27 CA CA2827787A patent/CA2827787A1/en not_active Abandoned
- 2012-03-27 MX MX2013011092A patent/MX2013011092A/es not_active Application Discontinuation
- 2012-03-27 CN CN2012800157134A patent/CN103476459A/zh active Pending
- 2012-03-27 BR BR112013025031A patent/BR112013025031A2/pt not_active IP Right Cessation
- 2012-03-27 AP AP2013007046A patent/AP2013007046A0/xx unknown
- 2012-03-27 JP JP2014501575A patent/JP2014515740A/ja not_active Ceased
- 2012-03-27 WO PCT/EP2012/055397 patent/WO2012130834A1/en not_active Ceased
- 2012-03-28 US US13/432,296 patent/US8821871B2/en active Active
- 2012-03-29 AR ARP120101085A patent/AR085758A1/es unknown
- 2012-03-29 UY UY0001033994A patent/UY33994A/es unknown
- 2012-03-29 TW TW101111195A patent/TW201302796A/zh unknown
-
2013
- 2013-07-25 IL IL227653A patent/IL227653A0/en unknown
- 2013-09-05 CL CL2013002551A patent/CL2013002551A1/es unknown
- 2013-09-20 CO CO13224736A patent/CO6771448A2/es unknown
- 2013-09-26 TN TNP2013000388A patent/TN2013000388A1/fr unknown
- 2013-10-25 EC ECSP13012997 patent/ECSP13012997A/es unknown
-
2014
- 2014-07-22 US US14/337,357 patent/US20140377265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MA34978B1 (fr) | 2014-03-01 |
| MX2013011092A (es) | 2013-12-06 |
| AP2013007046A0 (en) | 2013-08-31 |
| CN103476459A (zh) | 2013-12-25 |
| US20140377265A1 (en) | 2014-12-25 |
| ECSP13012997A (es) | 2013-12-31 |
| CA2827787A1 (en) | 2012-10-04 |
| CL2013002551A1 (es) | 2014-02-14 |
| EA201301090A1 (ru) | 2014-05-30 |
| TW201302796A (zh) | 2013-01-16 |
| AR085758A1 (es) | 2013-10-23 |
| IL227653A0 (en) | 2013-09-30 |
| US20120276123A1 (en) | 2012-11-01 |
| US8821871B2 (en) | 2014-09-02 |
| CO6771448A2 (es) | 2013-10-15 |
| KR20140009437A (ko) | 2014-01-22 |
| PE20140964A1 (es) | 2014-08-17 |
| BR112013025031A2 (pt) | 2017-08-01 |
| SG193552A1 (en) | 2013-11-29 |
| NZ613543A (en) | 2015-07-31 |
| TN2013000388A1 (en) | 2015-01-20 |
| JP2014515740A (ja) | 2014-07-03 |
| WO2012130834A1 (en) | 2012-10-04 |
| EP2691156A1 (en) | 2014-02-05 |
| UY33994A (es) | 2012-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000366A1 (en) | Anticoagulant antidotes | |
| MX2014012978A (es) | Regiones de anticuerpo modificado y sus usos. | |
| TN2013000388A1 (en) | Anticoagulant antidotes | |
| EP2706991A4 (en) | IMMUNOGENIC COMPOSITION WITH SEVERAL ANTIGENES, AND METHODS THEREFOR, AND USES THEREOF | |
| PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
| CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| BR112014030278A2 (pt) | anticorpo, e, composição. | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| TN2015000050A1 (en) | Methods of treating a tauopathy | |
| WO2013021279A3 (en) | Highly galactosylated antibodies | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| HK1218549A1 (zh) | 新型抗体框架 | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| WO2012109238A3 (en) | Methods for increasing immune responses using agents that directly bind to and activate ire-1 | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| EA201491455A1 (ru) | ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| UY35795A (es) | Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran | |
| HK1199842A1 (en) | Anti-siglec-15 antibodies and uses thereof | |
| UA70698U (ru) | Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства | |
| TH1301006508B (th) | องค์ประกอบที่รวมถึงโพลีเตตระฟลูออโรเอธิลีน และกระบวนการสำหรับการเตรียมองค์ประกอบของสิ่งนั้น | |
| CL2012001927A1 (es) | Anticuerpo capaz de neutralizar la actividad de un anticoagulante de dabigatran; método de fabricación de anticuerpo; kit que comprende al anticuerpo. |